Cast Your Vote: Durham's Mycovia Nominated for BIO Investor Forum

Mycovia logo

Durham’s Mycovia Pharmaceuticals is one of nine startups scrambling for last-minute votes in the “Buzz of BIO” Late Stage Leaders competition, part of the BIO Investor Forum taking place in San Francisco this October.

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The life science forum’s 2019 agenda is to analyze investment trends and opportunities for harnessing growth in venture-stage public companies.

North Carolina companies have been showcased at this international forum for four years now- last year Innovate Pharmaceuticals, T3D Therapeutics, and Catalent Biologics were up for winning prizes, just as Mycovia is this year.

Voting for the industry’s most innovative companies closes this Friday, September 13.

Buzz of BIO winners get to connect with potential investors willing to take their product to the next phase. Mycovia is looking to address  recurrent vulvovaginal candidiasis (RVVC) without geographic boundary in its global study; the condition affects up to 138 million women today and will grow in the next 10 years without treatment.

Noted for innovations in women’s health, Mycovia’s VT-1161 has received Qualified Infectious Disease Product and Fast Track designations by the U.S. Food and Drug Administration.  The RVVC candidate in FDA review qualifies Mycovia as a Late Stage Leader, with investments exceeding $25 million.

This comes only a few months after the company announced a collaboration with Jiangsu Hengrui Medicine of China to develop and commercialize VT-1161.

The BIO Investor Forum, scheduled for Oct. 22-23 at the Westin St. Francis Hotel in San Francisco, is an annual international conference that brings together bioscience companies and potential investors. Sponsored by the nonprofit Biotechnology Innovation Organization, the forum draws more than 1,000 participants.

Mycovia was founded in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. 

Lindsey Baron, NCBiotech Writer
Wed, 09/11/2019 - 16:54